Frontier IP portfolio company Exscientia joins the fight against COVID-19
Exscientia is a world leader in Artificial Intelligence (“AI”) driven drug discovery and this joint venture gives the portfolio company access to Calibr's collection of 15,000 clinically-ready molecules, which have already been shown to be safe for use in humans or have passed pre-clinical safety studies.
Exscientia will start by screening the collection to identify existing compounds that could be repurposed to tackle COVID-19. In time, the Company plans to use its AI to design even more effective compounds.
Frontier IP holds a 3.3 per cent equity stake in the Company.
Shares in frontier are up 5.5% in early morning trading.
Frontier IP Chief Executive, Neil Crabb, said: "Exscientia's aim is to use its AI to discover new, effective drugs quickly and efficiently, and we are optimistic the Company can make a significant contribution to the global fight against COVID-19.
"Other of our portfolio companies are directly involved in support efforts to combat COVID-19. These include The Vaccine Group, which is developing animal vaccines to combat the disease and related coronaviruses to prevent their future spread from animals into humans, and Elute Intelligence Holdings, which is using its technology to support scientists needing to sift complex datasets to identify the most relevant research for their work."
Frontier IP portfolio company Exscientia joins the fight against COVID-19
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.